Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

Completed · Phase 3

Conditions studied: Hypertension

In brief

To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.

Key facts

Study ID

NCT00281593

Run by

Boehringer Ingelheim

People needed

1354

Starts

2006-04-01

Last updated by the study team

2017-12-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients >=18 years of age with Stage I or II hypertension defined as:
• a mean seated cuff diastolic blood pressure >=95 and <=119 mmHg Main

You may not qualify if…

• Pregnant
• breast-feeding
• unwilling to use birth control during the study
• secondary hypertension
• SBP>=180 mmHg
• DBP>=120 mmHg
• severe renal dysfunction
• hepatic insufficiency
• stroke within the last 6 months
• myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months
• unstable or uncontrolled diabetes
• history of angioedema of either of the study drugs, and hypersensitivity to the study drugs.

Where it is running

• 1236.1.574 Boehringer Ingelheim Investigational Site — Tempe, Arizona, United States
• 1236.1.501 Boehringer Ingelheim Investigational Site — Tucson, Arizona, United States
• 1236.1.557 Boehringer Ingelheim Investigational Site — Tucson, Arizona, United States
• 1236.1.523 Boehringer Ingelheim Investigational Site — Buena Park, California, United States
• 1236.1.514 Boehringer Ingelheim Investigational Site — Concord, California, United States
• 1236.1.560 Boehringer Ingelheim Investigational Site — Encinitas, California, United States
• 1236.1.573 Boehringer Ingelheim Investigational Site — Long Beach, California, United States
• 1236.1.516 Boehringer Ingelheim Investigational Site — Los Angeles, California, United States
• 1236.1.529 Boehringer Ingelheim Investigational Site — Roseville, California, United States
• 1236.1.519 Boehringer Ingelheim Investigational Site — Tustin, California, United States
• 1236.1.543 Boehringer Ingelheim Investigational Site — Westlake Village, California, United States
• 1236.1.528 Boehringer Ingelheim Investigational Site — Boulder, Colorado, United States
• 1236.1.530 Boehringer Ingelheim Investigational Site — Farmington, Connecticut, United States
• 1236.1.572 Boehringer Ingelheim Investigational Site — DeLand, Florida, United States
• 1236.1.577 Boehringer Ingelheim Investigational Site — Hialeah, Florida, United States
• 1236.1.526 Boehringer Ingelheim Investigational Site — Jupiter, Florida, United States
• 1236.1.527 Boehringer Ingelheim Investigational Site — Largo, Florida, United States
• 1236.1.503 Anchor Research Center — Naples, Florida, United States
• 1236.1.520 Boehringer Ingelheim Investigational Site — New Port Richey, Florida, United States
• 1236.1.571 Boehringer Ingelheim Investigational Site — Pembroke Pines, Florida, United States
• 1236.1.565 Boehringer Ingelheim Investigational Site — Blue Ridge, Georgia, United States
• 1236.1.538 Boehringer Ingelheim Investigational Site — Meridian, Idaho, United States
• 1236.1.532 Boehringer Ingelheim Investigational Site — Peoria, Illinois, United States
• 1236.1.553 Boehringer Ingelheim Investigational Site — Avon, Indiana, United States
• 1236.1.511 Boehringer Ingelheim Investigational Site — Glendale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.